Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
RBGPF
0.1000
The Fort Worth Press - Novo Nordisk to slash prices of weightloss drugs in US
USD
-
AED 3.673054
AFN 62.999986
ALL 81.67505
AMD 377.839907
ANG 1.789731
AOA 916.999821
ARS 1379.719699
AUD 1.416671
AWG 1.80125
AZN 1.702312
BAM 1.660899
BBD 2.014946
BDT 122.253313
BGN 1.647646
BHD 0.377028
BIF 2965.5
BMD 1
BND 1.267451
BOB 6.912687
BRL 5.155106
BSD 1.000467
BTN 90.909168
BWP 13.201875
BYN 2.867794
BYR 19600
BZD 2.012042
CAD 1.370296
CDF 2129.999822
CHF 0.77385
CLF 0.02181
CLP 861.17979
CNY 6.884103
CNH 6.88039
COP 3712.19
CRC 474.370733
CUC 1
CUP 26.5
CVE 93.949847
CZK 20.566599
DJF 177.719711
DKK 6.344825
DOP 60.750165
DZD 129.886994
EGP 47.803097
ERN 15
ETB 154.150159
EUR 0.84921
FJD 2.200798
FKP 0.740353
GBP 0.741005
GEL 2.669922
GGP 0.740353
GHS 10.844995
GIP 0.740353
GMD 72.999699
GNF 8777.515562
GTQ 7.675193
GYD 209.308349
HKD 7.823525
HNL 26.519721
HRK 6.396897
HTG 131.278393
HUF 321.489502
IDR 16828.85
ILS 3.102585
IMP 0.740353
INR 90.91955
IQD 1310.5
IRR 1295153.999742
ISK 122.350012
JEP 0.740353
JMD 156.323908
JOD 0.709032
JPY 155.869022
KES 129.000302
KGS 87.450256
KHR 4015.999868
KMF 418.000242
KPW 900.013698
KRW 1442.530235
KWD 0.30663
KYD 0.833684
KZT 499.227216
LAK 21424.99953
LBP 89549.999859
LKR 309.529875
LRD 183.750216
LSL 15.959986
LTL 2.95274
LVL 0.60489
LYD 6.325012
MAD 9.169785
MDL 17.117599
MGA 4274.999934
MKD 52.328
MMK 2099.701293
MNT 3567.893063
MOP 8.061093
MRU 39.979752
MUR 46.29886
MVR 15.449623
MWK 1736.000016
MXN 17.17658
MYR 3.893801
MZN 64.395264
NAD 15.96013
NGN 1351.860477
NIO 36.709616
NOK 9.57071
NPR 145.455009
NZD 1.67649
OMR 0.384499
PAB 1.000459
PEN 3.3595
PGK 4.302029
PHP 57.688499
PKR 279.500744
PLN 3.581325
PYG 6455.228633
QAR 3.641055
RON 4.325994
RSD 99.735061
RUB 76.546784
RWF 1457
SAR 3.751072
SBD 8.045182
SCR 15.103711
SDG 601.497591
SEK 9.053205
SGD 1.26703
SHP 0.750259
SLE 24.501708
SLL 20969.49935
SOS 571.499154
SRD 37.804501
STD 20697.981008
STN 21.05
SVC 8.753025
SYP 110.548492
SZL 15.959899
THB 31.079735
TJS 9.479128
TMT 3.51
TND 2.86925
TOP 2.40776
TRY 43.844503
TTD 6.790312
TWD 31.381797
TZS 2567.83297
UAH 43.267779
UGX 3584.561165
UYU 38.738165
UZS 12205.000157
VES 406.86955
VND 26195
VUV 118.310075
WST 2.71223
XAF 557.047624
XAG 0.011468
XAU 0.000194
XCD 2.70255
XCG 1.803066
XDR 0.692412
XOF 556.498782
XPF 101.624946
YER 238.474994
ZAR 15.974775
ZMK 9001.221651
ZMW 18.833251
ZWL 321.999592
- Warner Bros. opens door to Paramount as bidding war heats up
- Newcastle complete cruise into Champions League last 16
- Leverkusen through to Champions League last 16 after Olympiacos draw
- Bodo/Glimt sink Inter to continue Champions League fairy tale
- Tech shares rebound as markets weigh AI impacts
- Puerto Vallarta: the Mexican paradise in flames over the killing of 'El Mencho'
- Sorloth treble helps Atletico past Brugge into Champions League last 16
- Louvre president hands in resignation to Macron: Elysee
- Iran says deal 'within reach' ahead of US talks
- Torrential rains leave 25 dead in Brazil, dozens missing
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
W.Lane--TFWP
